Is physical activity a future therapy for patients with Marfan syndrome?


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
10 02 2022
Historique:
received: 11 10 2021
accepted: 30 01 2022
entrez: 11 2 2022
pubmed: 12 2 2022
medline: 12 3 2022
Statut: epublish

Résumé

The international recommendations tend to avoid physical activity (PA) for patients with Marfan syndrome (MFS). However, exceptions have recently been made in the most recent recommendations for these patients, suggesting benefits from doing PA at low intensity only. Furthermore, there is no evidence that moderate aerobic or weight training can worsen the disease symptoms and increase mortality of MFS patients. The present review sums up the work carried out in the field of PA and MFS. The review aims to (1) identify the different types of exercise testing and training protocols and (2) discuss the feasibility and potentially beneficial nature of PA as an innovative way to manage MFS patients. The scientific literature was reviewed using the following words: Marfan syndrome, training, physical activity, evaluation, weight training, arterial disease, aneurysms, lung damage, aortic dissection, rupture. A total of 345 studies were prospected and 43 studies were included. A limited number of studies were done in humans, however one demonstrated the feasibility of the management of MFS patients with PA. There were potential beneficial effects of PA on arterial structures, but this review also showed deleterious effects when PA was conducted at high intensities, corresponding to 75-85% of the maximal oxygen uptake. However, these effects have only been reported in animal studies.

Identifiants

pubmed: 35144638
doi: 10.1186/s13023-022-02198-9
pii: 10.1186/s13023-022-02198-9
pmc: PMC8832740
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

46

Informations de copyright

© 2022. The Author(s).

Références

Am J Public Health. 1999 Oct;89(10):1578-80
pubmed: 10511845
Rheumatology (Oxford). 2007 Jun;46(6):957-62
pubmed: 17329351
Gene. 2016 Oct 10;591(1):279-291
pubmed: 27437668
BMC Psychiatry. 2017 Jul 17;17(1):253
pubmed: 28716062
Metabolism. 1991 Aug;40(8):836-41
pubmed: 1861633
Eur Heart J. 2021 Jan 1;42(1):17-96
pubmed: 32860412
J Am Heart Assoc. 2017 Sep 25;6(9):
pubmed: 28947563
J Cell Biol. 1986 Dec;103(6 Pt 1):2499-509
pubmed: 3536967
Pediatr Rep. 2018 Jan 04;9(4):7277
pubmed: 29383220
Br Med J. 1958 Dec 20;2(5111):1485-96
pubmed: 13608027
Am J Cardiol. 2006 Feb 15;97(4):571-7
pubmed: 16461059
J Appl Physiol (1985). 2017 Jul 1;123(1):147-160
pubmed: 28385916
J Am Coll Cardiol. 2015 Dec 1;66(21):2398-2405
pubmed: 26542664
J Child Orthop. 2020 Aug 1;14(4):343-348
pubmed: 32874369
J Am Heart Assoc. 2017 Sep 25;6(9):
pubmed: 28947564
Orphanet J Rare Dis. 2017 Jul 12;12(1):127
pubmed: 28701211
J Appl Physiol (1985). 2015 Sep 15;119(6):753-8
pubmed: 25190739
Prog Cardiovasc Dis. 2019 Sep - Oct;62(5):431-435
pubmed: 31711788
J Am Coll Cardiol. 2020 Mar 3;75(8):843-853
pubmed: 32130918
J Rehabil Med. 2003 Sep;35(5):221-8
pubmed: 14582554
Nat Rev Dis Primers. 2021 Sep 2;7(1):64
pubmed: 34475413
Lung. 2019 Aug;197(4):465-472
pubmed: 31089858
J Pediatr Orthop. 1999 May-Jun;19(3):283-8
pubmed: 10344308
Circulation. 1996 Jan 15;93(2):210-4
pubmed: 8548890
Chest. 1987 Mar;91(3):408-12
pubmed: 3816319
Cardiovasc Res. 2018 Mar 15;114(4):578-589
pubmed: 29360940
Congest Heart Fail. 2012 Nov-Dec;18(6):295-301
pubmed: 22536983
Annu Rev Med. 2000;51:481-510
pubmed: 10774478
J Appl Physiol (1985). 2003 Jul;95(1):20-5
pubmed: 12794092
Am J Epidemiol. 1993 Jan 1;137(1):74-81
pubmed: 8434575
Nature. 1991 Jul 25;352(6333):337-9
pubmed: 1852208
Circ Res. 2007 Aug 31;101(5):512-22
pubmed: 17641224
J Cell Biol. 1995 May;129(4):1165-76
pubmed: 7744963
Pediatr Exerc Sci. 2007 Nov;19(4):408-19
pubmed: 18089908
Expert Rev Cardiovasc Ther. 2019 Apr;17(4):251-266
pubmed: 30887852
Angiol Sosud Khir. 2004;10(4):22-9
pubmed: 15627131
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3819-23
pubmed: 10097121
J Neurol Neurosurg Psychiatry. 2003 May;74(5):633-8
pubmed: 12700307
J Am Coll Cardiol. 2005 Apr 19;45(8):1364-7
pubmed: 15837288
BMJ. 2004 Jan 24;328(7433):189
pubmed: 14729656
Am J Cardiol. 2005 Nov 1;96(9):1317-21
pubmed: 16253606
Med Sci (Paris). 2003 Dec;19(12):1242-50
pubmed: 14691749
ESC Heart Fail. 2017 Aug;4(3):356-359
pubmed: 28772048
J Am Soc Echocardiogr. 2003 Jul;16(7):745-50
pubmed: 12835661
J Appl Physiol (1985). 1991 Aug;71(2):644-50
pubmed: 1938738
Eur J Appl Physiol Occup Physiol. 1993;66(3):254-62
pubmed: 8477683
Circ Cardiovasc Imaging. 2019 Mar;12(3):e008129
pubmed: 30841707
Hypertension. 1986 Jan;8(1):37-44
pubmed: 3080370
Atherosclerosis. 2002 May;162(1):85-92
pubmed: 11947901
Circulation. 2008 Aug 12;118(7):785-91
pubmed: 18695204
Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):533-6
pubmed: 8756834

Auteurs

Steeve Jouini (S)

URP 3625-Institut des Sciences du Sport Santé de Paris (I3SP), Université de Paris, 75015, Paris, France.

Olivier Milleron (O)

Laboratory for Vascular Translational Science, INSERM U1148, Hôpital Bichat-Claude-Bernard, Université de Paris, Paris, France.
Centre National de Référence Pour le Syndrome de Marfan et Pathologies Apparentés, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.

Ludivine Eliahou (L)

Service de Cardiologie, Centre National de Référence Pour le Syndrome de Marfan et Apparentés, AP-HP, Hôpital Bichat, 75018, Paris, France.

Guillaume Jondeau (G)

Laboratory for Vascular Translational Science, INSERM U1148, Hôpital Bichat-Claude-Bernard, Université de Paris, Paris, France.
Centre National de Référence Pour le Syndrome de Marfan et Pathologies Apparentés, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.

Damien Vitiello (D)

URP 3625-Institut des Sciences du Sport Santé de Paris (I3SP), Université de Paris, 75015, Paris, France. damien.vitiello@u-paris.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH